Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by HIROKI UEDA
Palonosetron Exhibits Higher Total Control Rate Compared to First-Generation Serotonin Antagonists and Improves Appetite in Delayed-Phase Chemotherapy-Induced Nausea and Vomiting
Molecular and Clinical Oncology
Cancer Research
Oncology
Related publications
Palonosetron (Aloxi): A Second-Generation 5-Ht3 Receptor Antagonist for Chemotherapy-Induced Nausea and Vomiting
Baylor University Medical Center Proceedings
Medicine
Palonosetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting: Approval and Efficacy
Cancer Management and Research
Oncology
Preventing Chemotherapy-Induced Nausea and Vomiting With Netupitant/Palonosetron, the First Fixed Combination Antiemetic: Current and Future Perspective
Future Oncology
Medicine
Cancer Research
Oncology
Daily Palonosetron Is Superior to Ondansetron in the Prevention of Delayed Chemotherapy-Induced Nausea and Vomiting in Patients With Acute Myelogenous Leukemia
Cancer
Cancer Research
Oncology
Real-World Effectiveness of Palonosetron-Based Antiemetic Regimens: Preventing Chemotherapy-Induced Nausea and Vomiting
Journal of Comparative Effectiveness Research
Health Policy
Ramosetron Versus Palonosetron in Combination With Aprepitant and Dexamethasone for the Control of Highly-Emetogenic Chemotherapy-Induced Nausea and Vomiting
Cancer Research and Treatment
Cancer Research
Oncology
Evolving Role of Neurokinin 1-Receptor Antagonists for Chemotherapy-Induced Nausea and Vomiting
OncoTargets and Therapy
Oncology
Pharmacology
Cannabinoids for Control of Chemotherapy Induced Nausea and Vomiting: Quantitative Systematic
BMJ
Dronabinol for Chemotherapy-Induced Nausea and Vomiting Unresponsive to Antiemetics
Cancer Management and Research
Oncology
